vs
Side-by-side financial comparison of CACI INTERNATIONAL INC (CACI) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $2.4B, roughly 1.0× CACI INTERNATIONAL INC). Zoetis runs the higher net margin — 25.3% vs 5.5%, a 19.7% gap on every dollar of revenue. On growth, CACI INTERNATIONAL INC posted the faster year-over-year revenue change (8.5% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $221.4M). Over the past eight quarters, CACI INTERNATIONAL INC's revenue compounded faster (7.4% CAGR vs 4.4%).
CACI International Inc is a U.S.-headquartered multinational professional services and information technology firm. It delivers custom technology solutions, cybersecurity services, data analytics, and mission-critical operational support to government defense, intelligence, civilian agencies, and select private sector clients.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
CACI vs ZTS — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.4B | $2.4B |
| Net Profit | $130.4M | $603.0M |
| Gross Margin | — | 70.2% |
| Operating Margin | 9.7% | 31.9% |
| Net Margin | 5.5% | 25.3% |
| Revenue YoY | 8.5% | 3.0% |
| Net Profit YoY | 16.6% | 3.8% |
| EPS (diluted) | $5.88 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.2B | $2.4B | ||
| Q3 25 | $2.3B | $2.4B | ||
| Q2 25 | $2.3B | $2.5B | ||
| Q1 25 | $2.2B | $2.2B | ||
| Q4 24 | $2.1B | $2.3B | ||
| Q3 24 | $2.1B | $2.4B | ||
| Q2 24 | $2.0B | $2.4B |
| Q1 26 | $130.4M | — | ||
| Q4 25 | $123.9M | $603.0M | ||
| Q3 25 | $124.8M | $721.0M | ||
| Q2 25 | $157.9M | $718.0M | ||
| Q1 25 | $111.9M | $631.0M | ||
| Q4 24 | $109.9M | $581.0M | ||
| Q3 24 | $120.2M | $682.0M | ||
| Q2 24 | $134.7M | $624.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% |
| Q1 26 | 9.7% | — | ||
| Q4 25 | 9.3% | 31.9% | ||
| Q3 25 | 9.3% | 37.0% | ||
| Q2 25 | 9.0% | 36.7% | ||
| Q1 25 | 9.1% | 36.5% | ||
| Q4 24 | 8.6% | 31.6% | ||
| Q3 24 | 8.7% | 36.6% | ||
| Q2 24 | 9.7% | 33.0% |
| Q1 26 | 5.5% | — | ||
| Q4 25 | 5.6% | 25.3% | ||
| Q3 25 | 5.5% | 30.0% | ||
| Q2 25 | 6.9% | 29.2% | ||
| Q1 25 | 5.2% | 28.4% | ||
| Q4 24 | 5.2% | 25.1% | ||
| Q3 24 | 5.8% | 28.6% | ||
| Q2 24 | 6.6% | 26.4% |
| Q1 26 | $5.88 | — | ||
| Q4 25 | $5.59 | $1.37 | ||
| Q3 25 | $5.63 | $1.63 | ||
| Q2 25 | $7.11 | $1.61 | ||
| Q1 25 | $5.00 | $1.41 | ||
| Q4 24 | $4.88 | $1.29 | ||
| Q3 24 | $5.33 | $1.50 | ||
| Q2 24 | $5.97 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $158.0M | — |
| Total DebtLower is stronger | $5.2B | — |
| Stockholders' EquityBook value | $4.3B | $3.3B |
| Total Assets | $11.6B | $15.5B |
| Debt / EquityLower = less leverage | 1.21× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $158.0M | — | ||
| Q4 25 | $423.0M | — | ||
| Q3 25 | $133.0M | $2.1B | ||
| Q2 25 | $106.2M | $1.4B | ||
| Q1 25 | $223.9M | $1.7B | ||
| Q4 24 | $175.7M | $2.0B | ||
| Q3 24 | $440.7M | $1.7B | ||
| Q2 24 | $134.0M | $1.6B |
| Q1 26 | $5.2B | — | ||
| Q4 25 | $3.0B | — | ||
| Q3 25 | $2.8B | — | ||
| Q2 25 | $2.9B | — | ||
| Q1 25 | $3.1B | — | ||
| Q4 24 | $3.1B | — | ||
| Q3 24 | $1.8B | — | ||
| Q2 24 | $1.5B | — |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.1B | $3.3B | ||
| Q3 25 | $4.0B | $5.4B | ||
| Q2 25 | $3.9B | $5.0B | ||
| Q1 25 | $3.7B | $4.7B | ||
| Q4 24 | $3.7B | $4.8B | ||
| Q3 24 | $3.7B | $5.2B | ||
| Q2 24 | $3.5B | $5.0B |
| Q1 26 | $11.6B | — | ||
| Q4 25 | $8.9B | $15.5B | ||
| Q3 25 | $8.7B | $15.2B | ||
| Q2 25 | $8.6B | $14.5B | ||
| Q1 25 | $8.6B | $14.1B | ||
| Q4 24 | $8.5B | $14.2B | ||
| Q3 24 | $7.2B | $14.4B | ||
| Q2 24 | $6.8B | $14.2B |
| Q1 26 | 1.21× | — | ||
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.69× | — | ||
| Q2 25 | 0.75× | — | ||
| Q1 25 | 0.84× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.50× | — | ||
| Q2 24 | 0.44× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $248.3M | $893.0M |
| Free Cash FlowOCF − Capex | $221.4M | $732.0M |
| FCF MarginFCF / Revenue | 9.4% | 30.7% |
| Capex IntensityCapex / Revenue | 2.5% | 6.7% |
| Cash ConversionOCF / Net Profit | 1.90× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $641.6M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $248.3M | — | ||
| Q4 25 | $154.2M | $893.0M | ||
| Q3 25 | $171.1M | $938.0M | ||
| Q2 25 | $156.0M | $486.0M | ||
| Q1 25 | $230.3M | $587.0M | ||
| Q4 24 | $126.0M | $905.0M | ||
| Q3 24 | $34.7M | $951.0M | ||
| Q2 24 | $157.2M | $502.0M |
| Q1 26 | $221.4M | — | ||
| Q4 25 | $138.2M | $732.0M | ||
| Q3 25 | $154.1M | $805.0M | ||
| Q2 25 | $128.0M | $308.0M | ||
| Q1 25 | $214.1M | $438.0M | ||
| Q4 24 | $116.1M | $689.0M | ||
| Q3 24 | $23.2M | $784.0M | ||
| Q2 24 | $134.6M | $370.0M |
| Q1 26 | 9.4% | — | ||
| Q4 25 | 6.2% | 30.7% | ||
| Q3 25 | 6.7% | 33.5% | ||
| Q2 25 | 5.6% | 12.5% | ||
| Q1 25 | 9.9% | 19.7% | ||
| Q4 24 | 5.5% | 29.7% | ||
| Q3 24 | 1.1% | 32.8% | ||
| Q2 24 | 6.6% | 15.7% |
| Q1 26 | 2.5% | — | ||
| Q4 25 | 0.7% | 6.7% | ||
| Q3 25 | 0.7% | 5.5% | ||
| Q2 25 | 1.2% | 7.2% | ||
| Q1 25 | 0.7% | 6.7% | ||
| Q4 24 | 0.5% | 9.3% | ||
| Q3 24 | 0.6% | 7.0% | ||
| Q2 24 | 1.1% | 5.6% |
| Q1 26 | 1.90× | — | ||
| Q4 25 | 1.24× | 1.48× | ||
| Q3 25 | 1.37× | 1.30× | ||
| Q2 25 | 0.99× | 0.68× | ||
| Q1 25 | 2.06× | 0.93× | ||
| Q4 24 | 1.15× | 1.56× | ||
| Q3 24 | 0.29× | 1.39× | ||
| Q2 24 | 1.17× | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CACI
Segment breakdown not available.
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
